Kobo Biotech Ltd

NSE: AVONLIFE · BSE: 531541 · Pharmaceuticals & Biotechnology · 6 announcements

Share price: ₹3.69
Market cap: ₹8.79 Cr
Revenue (annual): ₹0.00 Cr
Net profit (annual): ₹-4.93 Cr
P/E (TTM): -1.8×Sector 49.1×
Promoter holding: 44.95%+0.00% QoQ
FII holding: 0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Insolvency Petition 3 Debt & Borrowing 1 Annual Report 1 Annual General Meeting 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

16 Jul 2026 12:31 IST BSE

Insolvency Petition

Kobo Biotech Insolvency Petition

Kobo Biotech reports that Beaufond Industries failed to implement the NCLT-approved resolution plan by the July 10 deadline. A Monitoring Committee meeting is convened for further action.

Execution: Implementation was due by 10 July 2026

Read the filing ↗

13 May 2026 11:11 IST BSE

Insolvency Petition

Kobo Biotech Insolvency Petition

NCLT approved Beaufond Industries' ₹70.11 Crore resolution plan for Kobo Biotech. The plan involves a merger, fresh equity issuance, and settlement of all existing liabilities.

Value: ₹70.11 Cr

Read the filing ↗

11 May 2026 19:33 IST BSE

Insolvency Petition

Kobo Biotech Insolvency Petition

NCLT approved Beaufond Industries' ₹70.11 Crore resolution plan for Kobo Biotech Limited. The plan ensures business continuity through debt settlement and restructuring.

Value: ₹70.11 Cr
Execution: 60 days

Read the filing ↗